Battling blood

How Global Blood's GBT440 could prevent RBC sickling in sickle cell disease

Global Blood Therapeutics Inc. is developing a small molecule that allosterically binds to hemoglobin and could be a disease-modifying treatment for sickle cell disease.

The product could provide an alternative to the only cure - bone marrow transplant - as well as to Phase III candidates that are seeking to reduce the duration or frequency of vaso-occlusive crisis. These acute pain crises are caused when sickled red blood cells block vessels, and usually require hospitalization and narcotics.

"We're not trying to treat crisis. We're trying to

Read the full 877 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE